Globeflex Capital L P Purchases New Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)

Globeflex Capital L P purchased a new stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN – Get Rating) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,279 shares of the company’s stock, valued at approximately $127,000. Globeflex Capital L P owned about 0.06% of UroGen Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of URGN. Millennium Management LLC boosted its position in UroGen Pharma by 292.8% during the second quarter. Millennium Management LLC now owns 616,245 shares of the company’s stock valued at $5,047,000 after purchasing an additional 459,341 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of UroGen Pharma by 53.8% during the second quarter. Wells Fargo & Company MN now owns 390,663 shares of the company’s stock worth $3,200,000 after purchasing an additional 136,671 shares during the period. Bank of America Corp DE increased its stake in shares of UroGen Pharma by 211.0% during the first quarter. Bank of America Corp DE now owns 128,317 shares of the company’s stock worth $1,118,000 after purchasing an additional 87,055 shares during the period. Citigroup Inc. increased its stake in shares of UroGen Pharma by 16,400.0% during the fourth quarter. Citigroup Inc. now owns 54,615 shares of the company’s stock worth $484,000 after purchasing an additional 54,284 shares during the period. Finally, State Street Corp increased its stake in shares of UroGen Pharma by 8.3% during the first quarter. State Street Corp now owns 548,241 shares of the company’s stock worth $4,775,000 after purchasing an additional 41,886 shares during the period. 58.90% of the stock is owned by institutional investors and hedge funds.

UroGen Pharma Trading Down 2.3 %

Shares of NASDAQ URGN traded down $0.25 during mid-day trading on Friday, hitting $10.45. 6,025 shares of the stock traded hands, compared to its average volume of 152,616. UroGen Pharma Ltd. has a twelve month low of $4.94 and a twelve month high of $16.11. The firm has a 50 day simple moving average of $10.45 and a two-hundred day simple moving average of $9.49.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on URGN. HC Wainwright reiterated a “buy” rating and set a $23.00 target price on shares of UroGen Pharma in a research note on Thursday, February 16th. Jefferies Financial Group downgraded UroGen Pharma from a “buy” rating to a “hold” rating and reduced their target price for the company from $35.00 to $10.00 in a report on Wednesday, February 8th.

UroGen Pharma Company Profile

(Get Rating)

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.